Copeptin is an independent prognostic factor for transplant-free survival in cirrhosis.
OBJECTIVE
Copeptin is a stable cleavage product of the arginine vasopressin (AVP) precursor and is equimolarly secreted with AVP. Copeptin is currently considered a reliable prognostic marker in a wide variety of diseases other than cirrhosis. We aimed to investigate the association between severity of cirrhosis and copeptin concentrations and to confirm whether copeptin is of prognostic significance in cirrhosis.


METHODS
One hundred and eighty-four cirrhotic patients hospitalized in two tertiary referral centres were studied. Serum copeptin was measured in samples obtained at hospital admission. Differences in serum copeptin between Child-Pugh classes were evaluated using the Kruskal-Wallis test. Cox proportional hazard regression and Kaplan-Meier analyses were performed to evaluate associations of copeptin and other possible prognostic factors with 6- and 12-month mortality.


RESULTS
Median serum copeptin (interquartile range) increased significantly through Child-Pugh classes A [5.4 (3.1-10.7) pmol/L], B [9.6 (6.0-17.3) pmol/L] and C [13.8 (5.8-34.1) pmol/L, P < 0.01]. Patients with serum copeptin >12.3 pmol/L displayed significantly higher mortality rates at 6 and 12 months as compared to those with serum copeptin ≤12.3 pmol/L (Log-rank test: P < 0.01). Serum copeptin >12.3 pmol/L was significantly associated with mortality, particularly at 6 months, independently of age, clinical parameters and Model for End stage Liver Disease (MELD), MELD-sodium and Child-Pugh score.


CONCLUSIONS
Serum copeptin concentration increases significantly along with the severity of cirrhosis as defined by the Child-Pugh classification. A high serum copeptin concentration predicts survival, particularly at 6 months, independently of liver-specific scoring systems in a heterogeneous population of hospitalized cirrhotic patients.
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Annarein J C
AJ
Kerbert
Department of Hepatology, University Hospital of Besançon, Besançon, France.
Delphine
D
Weil
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Hein W
HW
Verspaget
Department of Hepatology, University Hospital of Besançon, Besançon, France.
José-Philippe
JP
Moréno
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Bart
B
van Hoek
Department of Hepatology, University Hospital of Besançon, Besançon, France.
Jean-Paul
JP
Cervoni
Department of Hepatology, University Hospital of Besançon, Besançon, France.
Vincent
V
Di Martino
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Minneke J
MJ
Coenraad
Department of Hepatology, University Hospital of Besançon, Besançon, France.
Thierry
T
Thevenot
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D003661:Decision Support Techniques; D018572:Disease-Free Survival; D005260:Female; D005602:France; D006020:Glycopeptides / Q000097:blood*; D006760:Hospitalization; D006801:Humans; D053208:Kaplan-Meier Estimate; D008103:Liver Cirrhosis / Q000097:blood* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009426:Netherlands; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012307:Risk Factors; D012720:Severity of Illness Index; D062606:Tertiary Care Centers; D013997:Time Factors; D015854:Up-Regulation
D015415:Biomarkers; D006020:Glycopeptides; C048197:copeptins
biomarker; cirrhosis; copeptin; prognosis